The oncologist 2022 Mar 28

Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.

Abstract

Alpelisib and endocrine therapy provides ongoing treatment benefits for patients with HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer, according to updated findings from all 3 cohorts of the phase II BYLieve trial.

Related Questions

Would you offer capivasertib+fulvestrant in a patient with metastatic HR+ HER2 negative breast cancer with PTEN mutation who has progressed on fulvestrant plus ribociclib?

3 Answers

Mednet Member

Medical Oncology · Avita Health System

Patients who received prior Faslodex were excluded from the CAPItello-291 trial. I guess if you're being a purist you'd have to say no. Just thinking out loud: I don't see updated results, but there was a cohort (cohort B) in the BYLieve trial that was studying letrozole + Alpelisib in patients who ...